Beyond The Guidance: The Business Of Co-Development Combinations
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
FDA put together its well-received draft guidance on co-development of experimental drugs to be used in combination in less than a year, but even with regulators on board and the science burgeoning, the timeline for finding predictable ways for companies to actually collaborate on combining investigative cancer therapies looks to be much longer.